DelveInsight’s “Chemotherapy-Induced Diarrhea (CID) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy-Induced Diarrhea market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chemotherapy-Induced Diarrhea drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chemotherapy-Induced Diarrhea treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy-Induced Diarrhea (CID): An Overview
Chemotherapy-induced diarrhea (CID), also referred to as chemotherapy-related diarrhea (CRD), is a common side effect of cancer treatment. While cytotoxic agents are the main cause of Chemotherapy-Induced Diarrhea, targeted drugs, immunotherapy, and radiotherapy can also cause diarrhea. Chemotherapy-induced diarrhea presents a constant challenge in the efficient and tolerable treatment of cancer and is amongst the primary contributors to dose reductions, delays, and cessation of treatment.
Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease, and infections.
Current treatments for Chemotherapy-Induced Diarrhea aim to reduce the severity of symptoms rather than combating the pathophysiological mechanisms of dysfunction, and often result in worsening of already chronic GI symptoms or trigger the onset of a plethora of other side effects including respiratory depression, uneven heartbeat, seizures, and neurotoxicity.
Emerging treatments including those targeting the enteric nervous system present promising avenues to alleviate Chemotherapy-Induced Diarrhea. Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical outcomes and quality of life amongst cancer sufferers.
Chemotherapy-Induced Diarrhea (CID) Market Key Facts
The total Chemotherapy-Induced Diarrhea market size in the 7MM accounted for USD 80 million in 2022, which is expected to rise with a significant CAGR during the study period (2019–2032).
In 2022, the total incident cases of Chemotherapy-Induced Diarrhea were around 1,000,000 in the 7MM.
Among the selected 13 major indications, lung cancer contributed to the highest number of Chemotherapy-Induced Diarrhea cases in the US.
The incidence cases of Chemotherapy-Induced Diarrhea associated with lung cancer in the US were nearly 100,000 in 2022.
Among selected 13 major indications, colorectal cancer contributed to the highest number of Chemotherapy-Induced Diarrhea cases in Japan.
Chemotherapy-Induced Diarrhea (CID) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chemotherapy-Induced Diarrhea pipeline therapies. It also thoroughly assesses the Chemotherapy-Induced Diarrhea market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Chemotherapy-Induced Diarrhea drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy-Induced Diarrhea (CID) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chemotherapy-Induced Diarrhea epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chemotherapy-Induced Diarrhea epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chemotherapy-Induced Diarrhea Epidemiology, Segmented as –
Incident cases of selected cancer types
Total patients on chemotherapies by cancer type
Incident cases of Chemotherapy-Induced Diarrhea by selected cancer* types
Grade-specific incident cases of Chemotherapy-Induced Diarrhea
Total treated cases of Chemotherapy-Induced Diarrhea
Chemotherapy-Induced Diarrhea (CID) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chemotherapy-Induced Diarrhea market or expected to be launched during the study period. The analysis covers the Chemotherapy-Induced Diarrhea market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chemotherapy-Induced Diarrhea drugs based on their sale and market share.
The report also covers the Chemotherapy-Induced Diarrhea pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chemotherapy-Induced Diarrhea companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chemotherapy-Induced Diarrhea Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market
Chemotherapy-Induced Diarrhea (CID) Therapeutics Analysis
Findings from the survey conducted among oncologists in Europe regarding the handling of Chemotherapy-Induced Diarrhea unveiled a widespread agreement concerning the medications and intravenous fluid category employed for addressing patients with this condition. A substantial number of oncologists favored loperamide as the primary option for treating severe cases of Chemotherapy-Induced Diarrhea, with deodorized tinctures of opium, octreotide, and oral antibiotics following suit. Discrepancies in treatment methodologies became apparent when examining responses from countries with more than eight participants, yet loperamide remained the preferred choice for the majority of respondents.
Newer strategies and more effective agents are being developed to reduce the morbidity and mortality associated with CID. Recent research focusing on the prophylactic use of antibiotics, budesonide, probiotics, or activated charcoal still has to define the role of these drugs in the routine clinical setting. Whereas therapeutic management and clinical work-up of patients presenting with diarrhea after chemotherapy are rather well-defined, prediction and prevention of Chemotherapy-Induced Diarrhea is an evolving field. Current research focuses on establishing predictive factors for Chemotherapy-Induced Diarrhea like uridine diphosphate glucuronosyltransferase-1A1 polymorphisms for irinotecan or dihydropyrimidine-dehydrogenase insufficiency for fluoropyrimidines.
To further improve the treatment scenario, companies are actively exploring new therapeutic options. Currently, Napo Pharmaceuticals (Jaguar Health) is leading the therapeutics market with its drug candidate in the most advanced stage of clinical development.
Napo Pharmaceuticals, a wholly owned subsidiary of Jaguar Health, has initiated clinical trials investigating new treatment options. The company is investigating its candidate, MYTESI (crofelemer), to manage Chemotherapy-Induced Diarrhea in the Phase III clinical trial. Other than this, a few companies are also investigating their candidate in the pre-clinical development stage, such as OnQuality Pharmaceuticals (OQL105).
The Report Covers In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-injunction/chemotherapy-induced-diarrhea-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chemotherapy-Induced Diarrhea Competitive Intelligence Analysis
4. Chemotherapy-Induced Diarrhea Market Overview at a Glance
5. Chemotherapy-Induced Diarrhea Disease Background and Overview
6. Chemotherapy-Induced Diarrhea Patient Journey
7. Chemotherapy-Induced Diarrhea Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chemotherapy-Induced Diarrhea Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy-Induced Diarrhea Unmet Needs
10. Key Endpoints of Chemotherapy-Induced Diarrhea Treatment
11. Chemotherapy-Induced Diarrhea Marketed Therapies
12. Chemotherapy-Induced Diarrhea Emerging Drugs and Latest Therapeutic Advances
13. Chemotherapy-Induced Diarrhea Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy-Induced Diarrhea Market Outlook (In US, EU5, and Japan)
16. Chemotherapy-Induced Diarrhea Companies Active in the Market
17. Chemotherapy-Induced Diarrhea Access and Reimbursement Overview
18. KOL Views on the Chemotherapy-Induced Diarrhea Market
19. Chemotherapy-Induced Diarrhea Market Drivers
20. Chemotherapy-Induced Diarrhea Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Nasopharyngeal Carcinoma Market
“Nasopharyngeal Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Nasopharyngeal Carcinoma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Nasopharyngeal Carcinoma market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/oncology
